Canlyniadau Chwilio - Seock‐Ah Im

Mireinio'r Canlyniadau
  1. 1
    PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation

    PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation gan Ahrum Min, Seock Ah Im

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    HLA‐B27 association of autoimmune encephalitis induced by PD‐L1 inhibitor

    HLA‐B27 association of autoimmune encephalitis induced by PD‐L1 inhibitor gan Hyeyeon Chang, Yong‐Won Shin, Bhumsuk Keam, Miso Kim, Seock‐Ah Im, Soon‐Tae Lee

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

    Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer gan José Baselga, Javier Cortés, Seock‐Ah Im, Emma Clark, Graham Ross, Astrid Kiermaier, Sandra M. Swain

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies

    The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies gan Javier Cortés, Seock‐Ah Im, Esther Holgado, José Manuel Pérez-García, Peter Schmid, Mariana Chávez‐MacGregor

    Cyhoeddwyd 2017
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer

    Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer gan Sun Kyung Baek, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs?

    BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs? gan Peter Dubsky, Christian Jackisch, Seock‐Ah Im, Kelly K. Hunt, Chien‐Feng Li, Sheila Unger, Shani Paluch–Shimon

    Cyhoeddwyd 2024
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin

    Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin gan Sun Kim, H.S. Kim, Yu Kim, Do Oh, Seock‐Ah Im, Dongsoon Lee, Hyun-Soon Jong, Tae‐You Kim, Yung‐Jue Bang

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Antibiotic use during the last days of life in cancer patients

    Antibiotic use during the last days of life in cancer patients gan Dong Yoon Oh, J. Kim, Dong‐Wan Kim, Seock‐Ah Im, T.Y. KIM, D. S. Heo, Y-J. Bang, N.K. KIM

    Cyhoeddwyd 2006
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA

    Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the... gan Sandra M. Swain, Young‐Hyuck Im, Seock‐Ah Im, Valorie F. Chan, David Miles, Adam Knott, Emma Clark, Graham Ross, José Baselga

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index

    Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index gan Younak Choi, Do‐Youn Oh, Tae‐Yong Kim, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy

    The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy gan Younak Choi, Tae-Yong Kim, Do‐Youn Oh, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

    Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells gan Young‐Kwang Yoon, Hwang‐Phill Kim, Sae‐Won Han, Hyung-Seok Hur, Do Youn Oh, Seock‐Ah Im, Yung‐Jue Bang, Tae‐You Kim

    Cyhoeddwyd 2009
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

    Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer:... gan Johannes Ettl, Seock-Ah Im, Jungsil Ro, Norikazu Masuda, Marco Colleoni, Patrick Schnell, Eustratios Bananis, Dongrui R. Lu, Massimo Cristofanilli, Hope S. Rugo, Richard S. Finn

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Olaparib efficacy in patients with germline <scp>BRCA</scp>‐mutated, <scp>HER2</scp>‐negative metastatic breast cancer: Subgroup analyses from the phase <scp>III OlympiAD</scp> trial

    Olaparib efficacy in patients with germline <scp>BRCA</scp>‐mutated, <scp>HER2</scp>‐negative metastatic breast cancer: Subgroup analyses from the phase <scp>III OlympiAD</scp> tri... gan Elżbieta Senkus, Suzette Delaloge, Susan M. Domchek, Pierfranco Conté, Seock‐Ah Im, Binghe Xu, Anne Armstrong, Norikazu Masuda, Anitra Fielding, Mark E. Robson, Nadine Tung

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer

    Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer gan Chan‐Young Ock, Do‐Youn Oh, Joongyub Lee, Tae‐Yong Kim, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer

    Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract... gan Kyoung-Min Cho, Hyunkyung Park, Do‐Youn Oh, Tae‐Yong Kim, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer

    The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer gan Jiyoung Rhee, Sae‐Won Han, Do‐Youn Oh, Jee Hyun Kim, Seock‐Ah Im, Wonshik Han, In Ae Park, Dong‐Young Noh, Yung‐Jue Bang, Tae‐You Kim

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer

    Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer gan Dong-Hyeon Ha, Ahrum Min, Seongyeong Kim, Hyemin Jang, So Hyeon Kim, Hee Jun Kim, Han Suk Ryu, Ja‐Lok Ku, Kyung-Hun Lee, Seock‐Ah Im

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    The impact of race and ethnicity in breast cancer—disparities and implications for precision oncology

    The impact of race and ethnicity in breast cancer—disparities and implications for precision oncology gan Kelly A. Hirko, Gabrielle B. Rocque, Erica Reasor, Ammanuel Taye, Alex Daly, Ramsey Cutress, Ellen Copson, Dae‐Won Lee, Kyung-Hun Lee, Seock‐Ah Im, Yeon Hee Park

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    <i>ERCC1</i> and <i>ERCC2</i> Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis

    <i>ERCC1</i> and <i>ERCC2</i> Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis gan Ming Yin, Jingrong Yan, Eva Martinez‐Balibrea, Francesco Graziano, Heinz‐Josef Lenz, Hyo-Jin Kim, Jacques Robert, Seock‐Ah Im, Wei-Shu Wang, Marie-Christine Etienne-Grimaldi, Qingyi Wei

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: